Document:

Exhibit 10.19 Appointment as Executive Chairman

Exhibit 10.19

150 Orchard Road

Orchard Plaza, 08-02

Singapore, 238841

T: +65 6333 7234

F: +65 6333 7235

Dr. Martin Charles Faulkes

Eastwoods

The Chase

Oxshott

Surrey, KT22 0HR

13 July 2011

Dear Dr. Faulkes

Appointment as Executive Chairman

The board of directors of Singapore Volition Pte. Limited (the “Company”) is delighted that you have accepted our offer to the position as executive chairman (“Chairman”). Your appointment commenced on 22 March 2011.

This letter sets out the main terms of your appointment and supersedes your previous letter of appointment as Non Executive Director dated 23 September 2010. It is agreed between us that this is a contract for services and is not a contract of employment.

By accepting this appointment, you confirm that you are not subject to any restrictions which prevent you from holding office as a director.

The terms of your appointment are as follows:

1.

ROLE AND DUTIES

1.1

In addition to the normal duties imposed by law on Executive Directors, we would expect you to discharge the following functions and duties:

a.

to attend regular/scheduled board meetings at the Company’s registered office, either in person or via telephone conference, or such other place and on dates to be notified to you at least 10 business days in advance;

b.

to serve on the committee or committees of the Board as required and attend all committee meetings;

c.

to attend the Company’s annual general meeting, either in person or via telephone conference, to be held each year;

d.

to attend whether in person or via telephone conference any extraordinary general meetings or emergency board meetings which might be called from time to time;

e.

to engage in international travel, as required according to the needs of the Company and the direction of the Board of Directors.

f.

to carry out such other functions and duties as may be required of you.

1.2

In addition, in your role as Chairman you should:

(a)

chair the Board and general meetings of the Company;

(b)

set the Board’s agenda (primarily focused on strategy, performance, value creation and accountability) and ensure that adequate time is available for discussion of all agenda items, in particular strategic issues;

(c)

set clear expectations concerning the Company’s culture, values and behaviours and the style and tone of Board discussions;

(d)

ensure that the Board determines the nature and extent of the significant risks that the Company is willing to embrace in implementing its strategy;

(e)

ensure that the Board has effective decision-making processes and applies sufficient challenge to major proposals; and

(f)

ensure that Board committees are properly structured with appropriate terms of reference;

1.

FEES

1.1

You will receive an annual fee of US$90,000 (the “Fees”) which shall be paid in equal instalments monthly in arrears directly into your nominated bank account with Fees to begin accruing following;

(a)

the admission of the Company’s shares to a recognised exchange upon the listing, merger or reverse takeover of the Company; and

(b)

the Company being sufficiently funded in the opinion of the Board.

1.2

If in the opinion of the Board clause 2.1(b) is not satisfied, you shall receive a fee of US$6,250 per quarter commensurate with that received by non-executive directors until such time as the Company is sufficiently funded in the opinion of the Board.

1.3

You will be entitled to be reimbursed for any reasonable and agreed expenses incurred in the performance of your duties as Chairman of the Company subject to the production of receipts or other appropriate evidence of payment and compliance with the Company’s Travel and Expenses Policy (as amended from time to time) a copy of which will be provided.

1.4

The Company agrees to grant you an option to purchase up to 250,000 ordinary shares of the Company (the “Optioned Shares”) as fully paid and non-assessable at an exercise price of US$1.05 per Optioned Share the details of which will be governed by a separate option agreement

1.5

The Company will not be responsible for the deduction of income tax and national insurance or similar contributions in respect of your Fees or expenses payable as a result of your appointment and service as Chairman

2.

INDEPENDENT LEGAL ADVICE

2.1

The Company agrees to consider any request made by you for reimbursement of any reasonable legal fees incurred by you in relation to your position as Chairman (and for which you are not entitled to be indemnified pursuant to clause 3.2 below).  You will use reasonable efforts to make such request in writing prior to any such fees being incurred.  The Company agrees to reimburse such fees if the board in its absolute discretion decides that the legal advice sought was reasonably necessary in the proper discharge of your duties and it was not appropriate to obtain it from the professional advisors to the Company or any Committee.

2.2

The Company will indemnify you to the fullest extent permitted by law against all costs, charges, losses, damages and liabilities incurred by you in relation to any liability incurred defending any proceedings (whether civil or criminal) which relate to anything done or omitted or alleged to have been done or omitted by you as a chairman of the Company. To the extent that the Company’s memorandum and articles of association are or become inconsistent with this paragraph as a result of a change in Singaporean law, the Company agrees to propose, at the next annual or extraordinary general meeting of the shareholders of the Company, an amendment to the memorandum and articles of association to remove such inconsistency (any such amendment to be subject to approval by the shareholders at the relevant meeting).  The indemnity contained in this paragraph shall be without prejudice to any other indemnity to which you may be otherwise entitled.

3.

APPOINTMENT

3.1

Your appointment is subject to the articles of association of the Company, as amended from time to time, and will continue for an initial term of three years unless terminated by either party by giving to the other not less than 2 months’ prior written notice. The Board may invite you to serve for an additional period.

3.2

Your appointment will automatically terminate if you are removed from office by a resolution of the shareholders or if your office is vacated as set out in clause 4.3 and you will not be entitled to compensation in these events.

3.3

Your office as a director of the Company shall be immediately vacated in any of the following events:

(a)

if you become prohibited by law from acting as a director;

2

(b)

if you resign in writing or if you offer to resign and the directors resolve to accept such offer;

(c)

if you have a receiving order made against you or if you compound with your creditors generally;

(d)

by reason of mental incapacity, more particularly described in the Company’s articles of association;

(e)

if you shall be in breach of any terms set out in this letter which in the case of a breach capable of remedy is not remedied by you within 21 days of receipt by you of a notice from the Company specifying the breach and requiring its remedy;

(f)

if you shall be incompetent, guilty of gross misconduct and/or any serious or persistent negligence or misconduct in respect of your obligations under this letter;

(g)

if you fail or refuse after a written warning to carry out the duties reasonably and properly required of you under this letter;

(h)

or as otherwise provided for under the company’s Articles of Association

4.

CONFIDENTIALITY

4.1

In the course of your appointment and in the performance of your duties you will have access to and be entrusted with information (whether oral, written or any other form) containing or consisting of material of a technical, operational, administrative, economic, marketing, planning, business or financial nature or in the nature of intellectual property of any kind and relating to the Company and its parent or subsidiaries (the “Group”) (“Confidential Information”).  In connection with any Confidential Information:

(a)

you will at all times use Confidential Information for the purpose only of the proper discharge of your duties and will not disclose or permit to be disclosed to any person, firm or organisation outside the Group any Confidential Information or copies, summaries or reproductions of it in any form save if, and in so far as, you will be required so to do by law or by any competent regulatory authority.  If any proceedings are commenced or action taken which could result in you becoming compelled to disclose Confidential Information, you will immediately notify the Company in writing of such proceedings or action and, provided that you are first indemnified by the Company for any costs reasonably incurred in doing so, will take all available steps to resist or avoid such proceedings or action, including all steps that the Company may reasonably request and keep the Company fully and promptly informed of all matters and developments relating to it.  If you are obliged to disclose Confidential Information to any third party you will disclose only to that third party and you will seek to disclose only the minimum amount of Confidential Information consistent with your satisfying your obligations under this letter.  Furthermore, so far as is reasonably practicable, you will give the Company prior written notice of the Confidential Information you propose to disclose, the notice also containing a confirmation that your legal advisers’ opinion is that such disclosure is required, and you will give the Company an opportunity to discuss the relevant notice prior to the disclosure; and

(b)

at the expiration or sooner determination of your appointment you will surrender and deliver up to the Company all Confidential Information, provided that you may keep one copy of any Confidential Information for the sole purpose of defending any allegations or proceedings against you which relate to your appointment and service as a chairman of the Company.  For the avoidance of doubt, the undertakings in this clause 5 shall be unlimited in time and shall survive the termination of this agreement.

4.2

You shall not at any time (for whatever reason) use to the detriment or prejudice of the Company’s customers , suppliers or industry partners or of the Company or, except in the proper course of your duties under this letter of engagement, divulge to any person, firm or company information identifying in relation to the Company’s customers, suppliers or industry partners or their affairs or relating to the Company’s own affairs, which may come to your knowledge.

5.

OTHER PROVISIONS

5.1

For the avoidance of doubt, you are not required under the Company’s articles of association to hold any qualification shares.

5.2

We can confirm that the appropriate filings and notifications in connection with your appointment have been made with ACRA within the relevant time limits and that the Company secretary will supply you with a copy of the Company’s memorandum of association and any other information you may require.

5.3

It is accepted and acknowledged that you have business interests other than those of the Company and have declared any conflicts that are apparent at present.  In the event that you become aware of any potential conflicts of interest, these should be disclosed to the chairman and company secretary as soon as apparent.

3

5.4

It is the intention of the Company to take out directors’ and officers liability insurance following the intended listing of the company’s shares on a recognised exchange upon the listing, merger or reverse takeover of the Company.

5.5

This letter, together with any documents referred to in this letter sets out the entire agreement and understanding between the parties and supersedes all prior agreements, understandings or arrangements (oral or written) in respect of your engagement by the Company.

5.6

This letter shall be governed by and construed in accordance with Singapore law and the Singaporean courts shall have exclusive jurisdiction for all matters arising under it.

Please sign and return the enclosed duplicate of this letter indicating your acceptance of these terms.

Yours sincerely

/s/ Singapore Volition Pte. Limited 

For and on behalf of

Singapore Volition Pte. Limited

The above terms and conditions of appointment are hereby acknowledged and agreed this 13th  day of July 2011.

/s/Dr. Martin Charles Faulkes        

Dr. Martin Charles Faulkes

___________________________________________________________________________________________________________

Singapore Volition Pte. Limited

(Registered in Singapore with Company No. 201016543R)

e-mail : info@volitionrx.com  website : www.volitionrx.com

4Exhibit 10.20 Service Agreement

Exhibit 10.20

THIS AGREEMENT dated the 10 day of August 2011 is

BETWEEN:

(1)

SINGAPORE VOLITION PTE LIMITED a private limited company incorporated and registered in Singapore with registration number 201016543R and whose principal address is 150 Orchard Road, Orchard Plaza, 08-02, Singapore, 238841 (hereinafter "VOLITION")

AND

(2)

VOLITION RESEARCH LIMITED whose principal address is 82Z Portland Place, London, W1B 1NS (hereinafter "RESEARCH")

WHEREAS

VOLITION wishes to obtain certain services as provided in Schedule 1 of this Agreement and wishes to appoint RESEARCH to perform the services upon the terms herein provided;

RESEARCH is able and willing to provide the services to VOLITION on the terms and conditions set out herein.

NOW THE PARTIES HAVE AGREED AS FOLLOWS

1.

SERVICES TO BE PROVIDED

1.1

VOLITION appoints RESEARCH to provide the services as set out in Schedule 1 (the "Services"), upon the terms herein provided. Further services which are required by VOLITION may be added to the list of Services upon terms to be mutually agreed between the parties.

2.

CONSIDERATION

2.1

The fees for the provision of the Services by RESEARCH shall be one hundred and five thousand US Dollars (USD105,000.00) (the “Service Fee”) payable upfront and in full within 30 days of the execution of this Agreement.

2.2

VOLITION shall appoint a duly authorized representative or representatives to provide all necessary written instructions to RESEARCH in order for RESEARCH to carry out its obligations under this Agreement. RESEARCH shall only act upon written instructions received from the duly authorized representative(s).

3.

DURATION

3.1

The services to be provided by RESEARCH under this Agreement shall commence 10 August 2011 and shall continue for a period of 5 years (the “Term”).

4.

INFORMATION & TERMS

4.1

VOLITION will make available to RESEARCH any and all information that may reasonably be required for RESEARCH to carry out its duties in terms hereof.

4.2

VOLITION grants to RESEARCH a non exclusive, revocable licence to use the VOLITION business name, logo and other publically available material relevant to VOLITION in connection with the performance of the Services during the term of this Agreement subject to the prior written approval of VOLITION.

4.3

VOLITION shall have the non exclusive right to use the business name of RESEARCH (and for the avoidance of doubt The Dill Faulkes Educational Trust Ltd (“DFET”) and to represent RESEARCH as promoting the activities of VOLITION during the term of this Agreement subject to the prior written approval of RESEARCH.

4.4

VOLITION grants to RESEARCH and RESEARCH grants to VOLITION a non- exclusive, revocable licence to provide a hypertext link for the purpose of linking the VOLITION website with the RESEARCH (and for the avoidance of doubt DFET) website.

5.

DELEGATION

RESEARCH may:

5.1

subject to such terms and conditions mutually agreed between VOLITION and RESEARCH, from time to time delegate to any person, firm or company all or any of the services undertaken by it in terms hereof and may appoint or employ outside consultants or outside firms or independent agents.

6.

LOSS OR DAMAGE

6.1

The Services provided by RESEARCH shall be performed with due care and diligence.

6.2

RESEARCH is responsible for complying with all laws, rules and regulations applicable to the provision of the Services under this Agreement.

7.

INDEMNITY

7.1

RESEARCH hereby indemnifies and holds VOLITION harmless against all claims of whatever nature which may be brought against RESEARCH by any person whomsoever arising out of or in any way attributable to RESEARCH having acted in terms of this Agreement, and all legal costs (both solicitor-client and party-party), liability, damages or expenses which RESEARCH may suffer, sustain or incur in respect of or arising out of such claims.

8.

ARBITRATION

8.1 

The parties shall continuously act in good faith for the duration of this Agreement and in this regard any dispute, difference or question which may arise at any time hereafter between the parties arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, shall first be resolved by good faith negotiations between the parties which negotiations shall commence within thirty (30) days of the notice of dispute, difference or question.

8.2

Should the parties be unable to resolve the dispute, difference or question by good faith negotiations then the parties shall jointly refer such dispute, difference or question to the Singapore Mediation Centre for resolution. Should the mediator who shall be appointed by the Singapore Mediation Centre in accordance with its rules be unable to resolve the said dispute, difference or question to the satisfaction of the parties then clause 8.3 shall apply

8.3

Any dispute, difference or question which may arise at any time hereafter between the parties arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination which is not solved amicably between the parties in accordance with the provisions herein shall within thirty (30) days of the conclusion of the mediation in clause 8.2 herein be referred to and finally resolved by arbitration in Singapore in accordance with the Arbitration Rules of the Singapore International Arbitration Centre ("SIAC Rules") for the time being in force, which rules are deemed to be incorporated by reference in this clause. The reference to the SIAC Rules as understood in this Agreement refers to the rules which are most appropriate for the arbitration and the decision as to the most appropriate rules for the arbitration shall wholly and finally rest with the arbitrator appointed in accordance with this clause.

8.4

The tribunal shall consist of one arbitrator to be appointed by the Head/Chairman of the SIAC and the proceedings for the arbitration shall be conducted in the English language.

9.

GOVERNING LAW

9.1

This Agreement shall be governed and interpreted in every respect in accordance with the laws of Singapore.

10.

NOTICE

10.1

Notice to either party for the purposes of this Agreement or in respect of any legal proceedings, arbitration or otherwise shall be sent to the respective addresses set out below:

RESEARCH:

82Z Portland Place, London, W1B 1NS

Fax: +44 (0) 20 7307 3501

VOLITION:

150 Orchard Road, Orchard Plaza, 08-02, Singapore, 238841

Fax: +65 6333 7235

2

10.2

A notice is deemed to have been received:

(a)

if delivered personally, at the time of delivery; or

(b)

in the case of fax, at the time a notice of successful transmission is  received by the fax machine of the sender; or

(c)

in the case of pre-paid first class post, recorded delivery or registered post, or registered airmail, when received by the other party.

10.3 

Either party shall be entitled to change its aforesaid address to another address on giving the other party seven (7) days written notice of such proposed change of address.

11.

CONFIDENTIAL INFORMATION

11.1

Any information or data obtained by either party to this Agreement arising from the implementation of this Agreement shall be treated as strictly confidential by both the parties and their affiliates and shall not be divulged or permitted to be divulged to any person not being a party to this Agreement, without the prior written consent of the other party to this Agreement provided, however, that any information and data which is required to be furnished by law or contract or by any Stock Exchange on which the shares of either party to this Agreement are listed or quoted, may be so furnished. Every effort shall however be made to consult fully with the other party to this Agreement on all proposed releases of information with a view to avoiding untimely or damaging disclosures.

12.

ASSIGNMENT

12.1

Neither party may assign, in whole or in part, its rights and obligations under this Agreement, without the prior written consent of the other party (such consent not to be unreasonably withheld).

13.

WHOLE AGREEMENT

13.1 

This Agreement constitutes the whole agreement between the parties and supersedes any arrangements, understanding or previous agreement, whether orally, in writing or otherwise, between them relating to the subject matter they cover.

13.2 

Each party acknowledges that in entering into this Agreement, it does not rely on, and shall have no remedy in respect of, any statement, representation, assurance or warranty of any person other than as expressly set out in this Agreement.

14.

VARIATION AND WAIVER

14.1 

Any variation of this Agreement shall be in writing and signed by or on behalf of all parties.

14.2 

Any waiver of any right under this Agreement is only effective if it is in writing, and it applies only to the party to whom the waiver is addressed and the circumstances for which it is given and shall not prevent the party who has given the waiver from subsequently relying on the provision it has waived.

14.3 

No failure to exercise or delay in exercising any right or remedy provided under this Agreement or by law constitutes a waiver of such right or remedy or will prevent any future exercise in whole or in part thereof.

14.4 

Unless specifically provided otherwise, rights arising under this Agreement are cumulative and do not exclude rights provided by law.

15.

SEVERANCE

15.1 

If any provision of this Agreement (or part of a provision) is found by any court, tribunal, arbitrator(s) or administrative body of competent jurisdiction to be invalid, unenforceable or illegal, the other provisions shall remain in force.

15.2 

If any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, the provision shall apply with whatever modification is necessary to give effect to the commercial intention of the parties.

16.

AGREEMENT SURVIVES TERMINATION

16.1

This Agreement (other than obligations that have already been fully performed) remains in full force after expiry or termination and the expiry or termination of this Agreement shall be without prejudice to any other rights which have already accrued to either of the parties under this Agreement.

3

17. 

THIRD PARTY RIGHTS

17.1 

This Agreement is made for the benefit of the parties to them and their successors and permitted assigns, and is not intended to benefit, or be enforceable by anyone else and the provisions of the Contracts (Rights of Third Parties) Act shall not apply to this Agreement.

17.2

The right of the parties to terminate, rescind, or agree any amendment, variation, waiver or settlement under this Agreement is not subject to the consent of any person that is not a party to the Agreement.

Signed by the parties to have effect on the date written at the beginning of this agreement. 

/s/ Cameron Reynolds                       

CAMERON REYNOLDS

FOR AND ON BEHALF OF 

SINGAPORE VOLITION PTE. LIMITED

/s/ Dr. Martin Faulkes                       

DR MARTIN CHARLES FAULKES

FOR AND ON BEHALF OF 

VOLITION RESEARCH LIMITED

4

SCHEDULE 1

SERVICES

1.

Liaise with Cancer charities and trusts to raise the profile of VOLITION both in the UK and internationally.

2.

Liaise with various medical institutions (both non-profit and for profit) to promote and raise the profile of VOLITION, 

3.

Build and develop long term relationships between UK and international Cancer charities; medical institutions and VOLITION.

4.

Provide written reports to VOLITION on the activities undertaken and services provided under the terms of this Agreement. 

5.

Lobbying government, health organization and other policy makers on behalf of VOLITION and promote the socially responsible ethos of VOLITION.

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]